Treats multiple myeloma. Sold as Sarclisa, Sarclisa Escena. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 2 applications for Isatuximab-Irfc (sold as Sarclisa, Sarclisa Escena), first approved Mar 2, 2020, with 5 new uses approved and 0 published complete response letters.
| Sarclisa | Part B | $82.0M | +21% | 1,217 |
| Sarclisa | Part D | $10.8M | +79% | 119 |
| Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed MyelomaNewly Diagnosed Multiple Myeloma · Dana-Farber Cancer Institute | Phase 1 / Phase 2 | Not yet recruiting | May 22, 2026 |
| ELISA in Relapsed/Refractory MMRelapsed Refractory Multiple Myeloma (RRMM), Relapsed Refractory Multiple Myeloma · Massachusetts General Hospital | Phase 2 | Recruiting | Feb 18, 2025 |
| Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMMNewly Diagnosed Multiple Myeloma · Arbeitsgemeinschaft medikamentoese Tumortherapie | Phase 2 | Active, not recruiting | May 18, 2021 |
| Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple MyelomaRecurrent Multiple Myeloma, Refractory Multiple Myeloma · University of Washington | Phase 2 | Active, not recruiting | May 12, 2021 |
| Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple MyelomaRecurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma · OHSU Knight Cancer Institute | Phase 2 | Active, not recruiting | Apr 20, 2021 |
| Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple MyelomaMultiple Myeloma · Medical College of Wisconsin | Phase 2 | Active, not recruiting | Apr 8, 2021 |
| Isatuximab as Upfront Therapy for the Treatment of High Risk AL AmyloidosisAL Amyloidosis · Emory University | Phase 1 | Active, not recruiting | Feb 15, 2021 |
| Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)Smoldering Plasma Cell Myeloma · M.D. Anderson Cancer Center | Phase 2 | Active, not recruiting | Nov 9, 2016 |
| Mar 2, 2020 | SarclisaBLA 761113 · New molecular entity | Sanofi Aventis US | 8 | Marketed |
| Jul 9, 2026 | Sarclisa EscenaBLA 761445 · New dosage form | Sanofi-Aventis U.S. LLC | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA